Brought to you by 
Boston Scientific acquires Target Therapeutics for $1.1bn
20 Jul 1999
Executive Summary
Boston Scientific has acquired Target Therapeutics (minimally invasive catheters and devices for vascular brain disease) in a stock swap valued at $1.1bn.
Deal Industry
- Medical Devices
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com